- Report
- August 2025
- 90 Pages
North America
From €3092EUR$3,450USD£2,653GBP
- Report
- August 2019
- 264 Pages
Global
From €3580EUR$3,995USD£3,072GBP
- Report
- December 2024
- 332 Pages
Global
From €3761EUR$4,197USD£3,227GBP
- Report
- September 2023
- 249 Pages
Global
From €4765EUR$5,503USD£3,950GBP
- Report
- February 2025
- 315 Pages
Global
From €4301EUR$4,799USD£3,690GBP
- Report
- January 2025
- 363 Pages
Global
From €4301EUR$4,799USD£3,690GBP
- Report
- April 2022
- 116 Pages
Global
From €1164EUR$1,299USD£999GBP
- Report
- October 2021
- 145 Pages
Global
From €4301EUR$4,799USD£3,690GBP
- Report
- April 2024
- 305 Pages
Global
From €5248EUR$6,061USD£4,350GBP
- Report
- December 2022
- 437 Pages
Global
From €4765EUR$5,503USD£3,950GBP
- Report
- October 2024
- 295 Pages
Global
From €1327EUR$1,533USD£1,100GBP
- Report
- July 2024
- 335 Pages
Global
From €4436EUR$4,950USD£3,806GBP
- Report
- August 2026
Global
From €750EUR$896USD£666GBP
- Report
- August 2026
Global
From €600EUR$717USD£533GBP
- Report
- August 2026
Global
From €600EUR$717USD£533GBP
- Report
- August 2026
Global
From €450EUR$538USD£400GBP
- Report
- August 2026
Global
From €450EUR$538USD£400GBP
- Report
- August 2026
Global
From €450EUR$538USD£400GBP
- Report
- August 2026
Global
From €450EUR$538USD£400GBP
- Report
- August 2026
Global
From €300EUR$359USD£266GBP

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease.
T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more